Display options
Cite
Gronostaj K, Czech AK, Fronczek J, et al. Implementation of neoadjuvant chemotherapy in muscle invasive bladder cancer treatment in Poland: a single institution retrospective study. Cent European J Urol. 2019;72(2):100-105doi: 10.5173/ceju.2019.1892.
Gronostaj, K., Czech, A. K., Fronczek, J., Wiatr, T., Przydacz, M., Dudek, P., Curylo, L., Szczeklik, W., & Chlosta, P. (2019). Implementation of neoadjuvant chemotherapy in muscle invasive bladder cancer treatment in Poland: a single institution retrospective study. Central European journal of urology, 72(2), 100-105. https://doi.org/10.5173/ceju.2019.1892
Gronostaj, Katarzyna, et al. "Implementation of neoadjuvant chemotherapy in muscle invasive bladder cancer treatment in Poland: a single institution retrospective study." Central European journal of urology vol. 72,2 (2019): 100-105. doi: https://doi.org/10.5173/ceju.2019.1892
Gronostaj K, Czech AK, Fronczek J, Wiatr T, Przydacz M, Dudek P, Curylo L, Szczeklik W, Chlosta P. Implementation of neoadjuvant chemotherapy in muscle invasive bladder cancer treatment in Poland: a single institution retrospective study. Cent European J Urol. 2019;72(2):100-105. doi: 10.5173/ceju.2019.1892. Epub 2019 Jun 29. PMID: 31482015; PMCID: PMC6715095.
Copy Download .nbib Format: NLM
Share it on

Cent European J Urol. 2019;72(2):100-105. doi: 10.5173/ceju.2019.1892. Epub 2019 Jun 29.

Implementation of neoadjuvant chemotherapy in muscle invasive bladder cancer treatment in Poland: a single institution retrospective study.

Central European journal of urology

Katarzyna Gronostaj, Anna Katarzyna Czech, Jakub Fronczek, Tomasz Wiatr, Mikolaj Przydacz, Przemyslaw Dudek, Lukasz Curylo, Wojciech Szczeklik, Piotr Chlosta

Affiliations

  1. Jagiellonian University Medical College, Department of Urology, Cracow, Poland.
  2. Jagiellonian University Medical College, Department of Intensive Care and Perioperative Medicine, Cracow, Poland.

PMID: 31482015 PMCID: PMC6715095 DOI: 10.5173/ceju.2019.1892

Abstract

INTRODUCTION: Even though the survival benefit of neoadjuvant chemotherapy (NAC) in the treatment of muscle invasive bladder cancer (MIBC) is well established, NAC has not been widely used in Poland until recently. The aim of our study was to evaluate the utilization of NAC and its association with survival in MIBC.

MATERIAL AND METHODS: Patients who underwent radical cystectomy (RC) for MIBC between December 2012 and December 2017 were included in the study. Data were collected in the perioperative period and long-term observation was continued up to August 2018. Kaplan-Meier curves were used to estimate the probability of survival.

RESULTS: A sample of 155 patients with a median age of 65 (IQR: 60-69) years was analyzed. In this group, 79 patients (51%) were treated with NAC prior to RC. Patients in the NAC+RC group were younger, more often had a positive smoking history, and had lower preoperative levels of hemoglobin, white blood cells and C-reactive protein. A 90-day complication rate and mortality were similar in both groups and in the entire cohort were equal to 64.5% and 5.2%, respectively. The overall survival (OS) was on average 150 days longer in the RC+NAC group compared to the RC-only group when patients were followed-up for 3 years (95%CI:3 4 - 267; p = 0.011).

CONCLUSIONS: We demonstrated a high utilization of NAC at our institution. The use of NAC was associated with a better prognosis than RC alone and was not associated with an increased morbidity or mortality. Our results support the use NAC as a safe and effective treatment modality in MIBC.

Keywords: muscle invasive bladder cancer; neoadjuvant chemotherapy

Conflict of interest statement

The authors declare no conflicts of interest.

References

  1. J Clin Oncol. 2001 Feb 1;19(3):666-75 - PubMed
  2. Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6 - PubMed
  3. World J Urol. 2006 Aug;24(3):305-14 - PubMed
  4. Urology. 2007 Jan;69(1 Suppl):17-49 - PubMed
  5. Eur Urol. 2012 Jan;61(1):58-64 - PubMed
  6. Eur Urol. 2013 Feb;63(2):234-41 - PubMed
  7. Eur Urol. 2015 Jan;67(1):165-170 - PubMed
  8. Eur Urol. 2014 Sep;66(3):561-8 - PubMed
  9. Curr Urol Rep. 2014 Apr;15(4):394 - PubMed
  10. Cent European J Urol. 2015;68(3):278-83 - PubMed
  11. Oncotarget. 2017 Sep 18;8(49):86130-86142 - PubMed
  12. Urol Oncol. 2019 Mar;37(3):180.e1-180.e9 - PubMed
  13. World J Urol. 2019 Sep;37(9):1857-1866 - PubMed

Publication Types